【摘要】 aducanumab是一种可定向清除蓄积的可溶和不可溶性β-淀粉样蛋白斑块的人源化单克隆抗体。大脑中β-淀粉样蛋白斑块蓄积是阿尔茨海默病的病理特征之一。2021年6月，aducanumab获得美国FDA加速批准上市，用于治疗阿尔茨海默病，本文对其作用机制、药理作用、药动学、临床研究等进行综述。更多还原

【Abstract】 Aducanumab is a human monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease. In June 2021,aducanumab received accelerated approval from the US FDA for the treatment of Alzheimer’s disease. This article reviewed the mechanism of action,pharmacological studies,pharmacokinetics and clinical studies of aducanumab.更多还原